Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: nicotinic acid Clear all
Completed Not applicable Interventional

A Study to Evaluate the Effects of a Fiber Supplement on Gut Health

NCT07755735
View directory record Official record
Conditions
Gut Health, Bloating, Irregular Bowel Movements, Gastrointestinal Symptoms
Interventions
Active Supplement, Placebo Comparator
Dietary Supplement
Lead sponsor
Belli Welli Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism

NCT07649161
View directory record Official record
Conditions
Healthy Adult
Interventions
Niagen®
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 1 Interventional

Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)

NCT00976170
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
GC33(RO5137382), Sorafenib
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
5
States / cities
San Francisco, California • Miami, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT06624137
View directory record Official record
Conditions
OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Interventions
Serotonergic Psychedelic, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Hamden, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

NCT06919328
View directory record Official record
Conditions
Healthy Aging
Interventions
Niagen®, NAD+, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
40 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Not applicable Interventional Results available

Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer

NCT00544167
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Sorafenib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
8
States / cities
Jacksonville, Florida • Orlando, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer

NCT00414388
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sorafenib
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Niles, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer

NCT01189370
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
sorafenib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 4 Interventional Results available

Niacin and Endothelial Function in Early CKD

NCT00852969
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Niacin, Active Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 1, 2026, 6:27 PM EDT
Recruiting Phase 3 Interventional

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT06861088
View directory record Official record
Conditions
Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Kinisoquin™, Placebo
Drug
Lead sponsor
Quercis Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Ventura, California • Miami Lakes, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated Phase 1 Interventional

BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma

NCT00287495
View directory record Official record
Conditions
Kaposi's Sarcoma, HHV-8, KSHV
Interventions
BAY 43-9006
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

NCT00483301
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Sorafenib (BAY 43-9006), ABI-007(Abraxane)
Drug
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Los Angeles, California • Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

NCT02069145
View directory record Official record
Conditions
Hepatocellular Cancer, Liver Cancer
Interventions
OMP-54F28 with Sorafenib
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)

NCT00913081
View directory record Official record
Conditions
Flushing
Interventions
Quercetin, Placebo
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 1, 2026, 6:27 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
20
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Not yet recruiting Phase 2 Interventional

Pilot Study: Effects of Nimodipine on Alcohol Drinking

NCT06900998
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Nimodipine
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

NCT01264705
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 1, 2026, 6:27 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Validation of NAD+ Measurements for Human Clinical Studies

NCT07416786
View directory record Official record
Conditions
Healthy Adults
Interventions
Oral NR Supplementation
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT00714948
View directory record Official record
Conditions
Bladder Cancer, URINARY BLADDER
Interventions
gemcitabine and cisplatin plus sorafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated Phase 2 Interventional

Research Study for Patients With Metastatic Renal Cell Carcinoma

NCT00110344
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Nexavar (Sorafenib, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

Nutrition, Immunology and Epidemiology of Tuberculosis

NCT00197704
View directory record Official record
Conditions
Tuberculosis
Interventions
Multivitamins, Placebo
Dietary Supplement · Other
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years and older
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2010 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 1 Interventional

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

NCT02779283
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate
Drug · Device · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated Phase 1 Interventional Results available

A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer

NCT00779311
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
sorafenib, bevacizumab, mFOLFOX6 regimen
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Macon, Georgia • Billings, Montana • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 1, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

NCT04750616
View directory record Official record
Conditions
Ischemia Reperfusion Injury, Myocardial Injury, Acute Kidney Injury
Interventions
Niacinamide, Placebo
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 1, 2026, 6:27 PM EDT